237 related articles for article (PubMed ID: 11602028)
1. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
[TBL] [Abstract][Full Text] [Related]
2. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
3. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
4. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Forette F; Anand R; Gharabawi G
Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
[TBL] [Abstract][Full Text] [Related]
6. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
[TBL] [Abstract][Full Text] [Related]
7. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
[TBL] [Abstract][Full Text] [Related]
8. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
Desai A; Grossberg G
Expert Opin Pharmacother; 2001 Apr; 2(4):653-66. PubMed ID: 11336614
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine for Alzheimer's disease.
Birks J; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
11. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Hauber AB; Gnanasakthy A; Mauskopf JA
Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
Stefanova E; Wall A; Almkvist O; Nilsson A; Forsberg A; Långström B; Nordberg A
J Neural Transm (Vienna); 2006 Feb; 113(2):205-18. PubMed ID: 16049637
[TBL] [Abstract][Full Text] [Related]
13. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
Finkel SI
Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465
[TBL] [Abstract][Full Text] [Related]
14. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
Teipel SJ; Drzezga A; Bartenstein P; Möller HJ; Schwaiger M; Hampel H
Psychopharmacology (Berl); 2006 Jul; 187(1):86-94. PubMed ID: 16767418
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
16. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Kumar V; Anand R; Messina J; Hartman R; Veach J
Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
[TBL] [Abstract][Full Text] [Related]
17. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
18. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
[TBL] [Abstract][Full Text] [Related]
19. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
20. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
